Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Free Cash Flow (2016 - 2025)

Agios Pharmaceuticals' Free Cash Flow history spans 14 years, with the latest figure at -$100.2 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 25.67% year-over-year to -$100.2 million; the TTM value through Dec 2025 reached -$377.3 million, up 3.64%, while the annual FY2025 figure was -$377.3 million, 3.64% up from the prior year.
  • Free Cash Flow reached -$100.2 million in Q4 2025 per AGIO's latest filing, down from -$88.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $7.9 million in Q4 2021 to a low of -$163.2 million in Q3 2021.
  • Average Free Cash Flow over 5 years is -$84.8 million, with a median of -$80.2 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: skyrocketed 107.11% in 2021, then tumbled 933.77% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at $7.9 million in 2021, then crashed by 933.77% to -$66.3 million in 2022, then dropped by 8.3% to -$71.8 million in 2023, then tumbled by 87.79% to -$134.8 million in 2024, then rose by 25.67% to -$100.2 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Free Cash Flow are -$100.2 million (Q4 2025), -$88.4 million (Q3 2025), and -$76.5 million (Q2 2025).